Epidemiology

Type 2 diabetes in Mainland China: Shifting treatment patterns

Mainland China has gone through a series of regulatory and reimbursement reforms in recent years in an effort to keep pace with its dynamic economic and demographic landscape. Clarivate market assessment expert Karan Verma discusses the role of these reforms in Mainland China’s type 2 diabetes market and how they could broaden access to innovative […]

Mainland China’s anticipated biosimilar boom – potential and key drivers of the market

The market of major biologics in Mainland China has tripled since 2017, with the potential to grow five-fold over the next ten years – which could drive biosimilars growth. Clarivate expert Akash Saini discusses this market’s potential and key drivers.    The approval of Shanghai Henlius Biotech’s HLX01—a biosimilar of rituximab (Roche’s MabThera)—in February 2019 […]